iBio (IBIO) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IBIO iBio Inc IBIO
30 GF Score
Price $1.44
GF Value $0.05
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is iBio Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

IBIO vs RNTX, RANI, OSTX: Short Percentage of Float Comparison

For the Biotechnology subindustry, iBio's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iBio Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, iBio's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where iBio's Short Percentage of Float falls into.


IBIO
30GF Score
iBio Inc IBIO
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is iBio (IBIO) Overvalued in 2026?

Based on GuruFocus' analysis, iBio stock appears to be overvalued. The current stock price of $1.44 is trading 2770% above its estimated GF Value™ of $0.05. GuruFocus considers iBio to be Significantly Overvalued.

Key valuation signals for IBIO:

  • Short Percentage of Float:
  • GF Value™: $0.05 vs. price of $1.44 (2770% above fair value)
  • GF Score™: 30/100 with 2 warning signs

No single metric tells the full story. See the IBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

iBio Business Description

Other Exchanges 0JV0:Germany
Address 11750 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
30GF Score

Get the complete analysis for IBIO

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.44
Price
$0.05
GF Value